Edwards Lifesciences Strategy and Business Model

Executive Overview

Edwards Lifesciences is a cardiovascular medical-technology company best known for transcatheter aortic valve replacement (TAVR), surgical tissue valves, and newer transcatheter mitral and tricuspid therapies. Edwards’ strategy is built around structural heart disease: defend leadership in TAVR, expand into adjacent mitral and tricuspid interventions, and use clinical evidence, physician training, and premium device engineering to widen adoption. Historically, Edwards also owned a critical care monitoring business. In June 2024, it announced an agreement to sell that product group to Becton, Dickinson and Company (BD), a portfolio move that underscored management’s push to make Edwards a more focused structural-heart company.

Edwards is headquartered in Irvine, California. Its roots go back to 1958 and the work that led to the Starr-Edwards heart valve, while the current public company was spun out of Baxter in 2000. The company sells globally to hospitals and heart programs, with especially strong positions in the United States, Europe, and Japan. Edwards reported about $6.0 billion of revenue in FY2023. Strategically, it is an important company to watch because growth depends not just on product launches, but on clinical trials, regulatory approvals, reimbursement, physician training, manufacturing quality, and hospital workflow adoption.

Edwards Lifesciences at a Glance

Logo
Common name	Edwards Lifesciences
Full legal name	Edwards Lifesciences Corporation
Headquarters	Irvine, California, United States
Ownership	Public company; widely held institutional ownership; no controlling shareholder
Ticker	EW
Exchange	NYSE - New York Stock Exchange
Market Cap	$49.97B
Revenue (FY2024)	$5.44B
Founding / major historical milestones	Roots in 1958; first successful Starr-Edwards artificial heart valve implanted in 1960; spun out of Baxter in 2000; built global TAVR leadership in the 2010s; announced sale of Critical Care to BD in 2024
Industry or industries	Medical devices; cardiovascular technology; structural heart therapies
Key products or services	TAVR systems, transcatheter mitral and tricuspid repair/replacement systems, surgical tissue valves, and historically critical care monitoring systems and disposables
Geographic footprint	Global commercial footprint across North America, Europe, Japan, Asia-Pacific, Latin America, and other international markets
Business segments as officially reported	One reportable segment; revenue disclosed by product group in FY2023: TAVR, Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care
Company website	https://www.edwards.com

1. What Is the Strategy of Edwards Lifesciences?

1a. What is the winning aspiration of Edwards Lifesciences?

Edwards frames its mission around helping patients live longer and healthier lives through innovative medical solutions. In strategic terms, winning means being the leading structural heart company, not just a broad cardiac device supplier. Public communications through FY2023 and the first half of 2024 point to a clear aspiration: maintain TAVR leadership, convert newer mitral and tricuspid platforms into meaningful growth businesses, and use clinical evidence and physician adoption to expand the treatable patient pool. The June 2024 announcement to sell the Critical Care product group to BD reinforced that aspiration by signaling a more focused future portfolio centered on structural heart.
1b. Where does Edwards Lifesciences play?

Edwards plays in high-acuity cardiovascular interventions performed mainly in hospitals with advanced heart programs. Its core arenas are severe aortic stenosis treated through TAVR, surgical valve replacement and repair, and transcatheter mitral and tricuspid therapies. Historically it also played in operating room and intensive care hemodynamic monitoring. Geographically, Edwards focuses on markets where reimbursement, physician training, and hospital infrastructure can support complex procedures, especially the United States, Europe, Japan, and selected growth markets internationally.
1c. How does Edwards Lifesciences plan to win?

Edwards competes through differentiation, not low cost. Its recipe for winning combines premium device design, proprietary tissue and catheter technologies, deep clinical evidence, regulatory execution, and intensive physician training. In TAVR, Edwards has long benefited from a strong product franchise, established heart-team relationships, and broad procedural know-how. In newer mitral and tricuspid therapies, it is trying to replicate that playbook: bring differentiated platforms to market, support them with data, and build physician comfort through case support and education. The announced portfolio move away from Critical Care also suggests that management believes focus itself is a competitive advantage.
1d. What capabilities must Edwards Lifesciences have in place?

To execute this strategy, Edwards needs unusually strong capabilities in five areas: device engineering and biomaterials science; global clinical trial design and execution; regulatory affairs and post-market surveillance; precision manufacturing and quality systems for implantable devices; and specialized commercial support for hospitals and physicians. Reimbursement and health-economics capabilities also matter because hospitals need proof that new valve procedures improve outcomes and fit within payment frameworks.
1e. What management systems does Edwards Lifesciences require?

Edwards needs management systems that are disciplined enough for a regulated implantable-device company and flexible enough for innovation. That includes rigorous quality-control systems, supplier qualification, complaint handling, and post-market safety monitoring; portfolio-review processes that allocate capital across TAVR, TMTT, and surgical programs; milestone tracking for clinical and regulatory programs; and commercial metrics tied to physician adoption, account productivity, and geographic expansion. Capital-allocation discipline is also central because Edwards must balance heavy R&D spending, manufacturing investment, share repurchases, and selective tuck-in deals.

2. What Are the Current Strategic Initiatives of Edwards Lifesciences?

Sharpen the portfolio around structural heart. In June 2024, Edwards announced an agreement to sell its Critical Care product group to BD for $4.2 billion in cash. The strategic logic was straightforward: simplify the company and concentrate management attention, capital, and R&D on structural heart therapies.
Defend and extend TAVR leadership. Edwards continues to invest in the SAPIEN franchise through product iteration, physician training, clinical evidence, and broader geographic penetration. The company’s public messaging has consistently emphasized durability data, procedural ease of use, and widening access to patients who remain untreated or undertreated.
Scale transcatheter mitral and tricuspid therapies. This is the most important next growth vector beyond TAVR. Edwards has been commercializing PASCAL-based repair systems and, in 2024, received U.S. Food and Drug Administration approval for EVOQUE in tricuspid regurgitation, creating a new launch platform in a large but still early market.
Grow the surgical structural heart franchise through RESILIA. Edwards has pushed RESILIA tissue technology across surgical valves such as INSPIRIS RESILIA and MITRIS RESILIA, aiming to support durability messaging and remain relevant in surgery even as catheter-based treatments expand.
Maintain a high clinical-evidence tempo. Edwards’ strategy depends on clinical trials, real-world evidence, and regulatory expansions. The company’s current initiatives therefore include continued investment in pivotal studies, post-approval data, and physician training programs that can turn clinical data into routine practice.
Expand internationally without diluting execution quality. Edwards continues to pursue adoption outside its largest developed markets, but its model requires careful center selection, reimbursement work, and training. That makes international expansion a strategic initiative, not just a geographic sales task.

3. What Is the Business Model of Edwards Lifesciences?

What customers actually buy: Hospitals and heart programs buy high-value implantable devices, delivery systems, and procedure-related tools for treating structural heart disease. In its historical Critical Care business, customers also bought monitoring platforms, sensors, catheters, and algorithm-enabled disposables.
Recurring or repeat-driven versus one-time: Edwards is not a subscription business. At the patient level, most valve implants are one-time procedures. At the account level, however, the revenue base is highly repeat-driven because hospitals perform procedures continuously. Critical Care historically added a more classic capital-plus-consumables model, where installed monitors generated ongoing disposable demand.
How pricing power works: Pricing power comes from differentiation. Edwards sells products that are clinically important, heavily regulated, and hard to replicate. When a product has strong outcomes data, physician familiarity, and hospital workflow integration, price pressure is lower than in more commoditized device categories. That said, pricing is still shaped by tenders, hospital procurement discipline, and international reimbursement systems.
Why the business mix matters: TAVR has historically been the main revenue and profit engine. TMTT is much smaller but strategically important because it can become the next major growth platform. Surgical structural heart helps Edwards serve a broader continuum of care and maintain surgeon relationships. Critical Care historically added recurring disposables and broader hospital touchpoints, but the announced 2024 sale shows management preferred greater focus over diversification.
What drives gross margin, operating margin, and cash generation: Gross margins benefit from premium pricing, high-value clinical utility, and relatively low raw-material content versus selling price. Operating margins are influenced by heavy spending on R&D, clinical trials, specialized field support, and physician training. Cash generation is generally strong because Edwards operates in a high-margin medtech category, although inventory, manufacturing controls, and trial spending absorb capital.
Revenue model: The model is primarily per-procedure device sales, supplemented historically by a capital-equipment-and-consumables model in Critical Care. It is best understood as a procedure-volume-driven medtech model rather than a software, rental, or subscription model.

4. What Products and/or Services Does Edwards Lifesciences Sell?

TAVR

Edwards’ flagship business is TAVR, led by the SAPIEN family of transcatheter heart valves and related delivery systems. This is the company’s most important product category by revenue and strategic influence. TAVR is central to Edwards’ identity, physician relationships, and clinical reputation.

Transcatheter Mitral and Tricuspid Therapies (TMTT)

This portfolio includes repair and replacement systems for mitral and tricuspid valve disease. Key brands include PASCAL and EVOQUE, with other platforms and pipeline programs supporting Edwards’ push into large adjacent structural-heart markets. TMTT is still earlier-stage than TAVR, but it is one of Edwards’ highest-priority growth areas.

Surgical Structural Heart

Edwards also sells surgical tissue valves and related products, including INSPIRIS RESILIA, MITRIS RESILIA, and legacy Carpentier-Edwards valve lines. This business matters strategically because it keeps Edwards relevant with cardiac surgeons and supports a broader structural-heart portfolio, even as minimally invasive procedures gain share.

Critical Care

Historically, Edwards sold hemodynamic monitoring platforms and disposables used in operating rooms and intensive care units. Key products included HemoSphere, FloTrac, Acumen, and Swan-Ganz catheters. This business was strategically useful because it had more recurring consumable economics, but in June 2024 Edwards announced an agreement to divest it to BD.

Which offerings matter most?

TAVR has been the main revenue driver. TMTT appears to be the most important newer growth category. Surgical structural heart is an important profit and relationship business, while Critical Care has historically been valuable but non-core to the company’s structural-heart-led future.

5. What Are the Key Competitors or Peers of Edwards Lifesciences?

Competition for Edwards varies by therapy area. It does not face one identical rival across the whole portfolio.

Medtronic: Edwards’ clearest large-scale direct rival in TAVR through the Evolut franchise. Medtronic also competes in surgical heart valves and other cardiovascular devices.
Abbott: A major structural-heart competitor, especially in mitral and tricuspid repair through MitraClip and TriClip, and also present in transcatheter valve therapies through its Navitor platform.
Boston Scientific: More of a structural-heart and interventional-cardiology peer than a direct across-the-board rival, but competitive in selected valve markets and adjacent physician relationships.
Artivion: A smaller but relevant peer in surgical heart valves and aortic surgery, particularly on the surgical side of structural heart.
Meril Life Sciences: A regional TAVR competitor, especially in India and some export markets, illustrating that Edwards also faces emerging-market challengers.
Venus Medtech: A China-based competitor in transcatheter valve therapies, relevant where local market structure and domestic approvals matter.
MicroPort CardioFlow: Another China-based structural-heart competitor, especially in transcatheter valve technologies.
Getinge and Masimo: These are closer peers for Edwards’ historical Critical Care business rather than for structural heart. They matter because competition in monitoring uses different economics and channels than valve intervention.

6. What Is the Marketing Strategy of Edwards Lifesciences?

Edwards’ marketing model is primarily clinical and account-based, not consumer-oriented. The company markets through published evidence, conference presence, physician education, proctoring, hospital-economics discussions, and disease-awareness efforts tied to underdiagnosed valve disease. In practice, the most important “marketing” assets are not slogans; they are trial data, product performance, and the field teams who help heart programs adopt complex procedures safely.

Brand marketing matters, but mainly inside the clinician community. SAPIEN, PASCAL, EVOQUE, and RESILIA are important brands because physician confidence and procedural familiarity affect adoption. Performance marketing in the digital-advertising sense is less central than in consumer or software businesses. Channel marketing matters in distributor-led international markets, while field marketing matters in major hospital accounts. Overall, marketing is a supporting capability, but a specialized and strategically important one because adoption in medtech often depends on education and evidence rather than broad awareness alone.

7. What Are the Key Customer Segments of Edwards Lifesciences?

Tertiary hospitals and heart centers: These are the core customers for TAVR and TMTT. They provide the infrastructure, imaging, heart-team staffing, and procedural volume needed for complex valve therapies.
Interventional cardiologists, cardiac surgeons, and heart teams: These clinicians are not always the legal buyer, but they are the key specifiers and adopters. Their trust in clinical data and device performance is essential.
Hospital administrators and value-analysis committees: They matter because structural-heart programs require capital, training, reimbursement planning, and careful economic justification.
Operating room and intensive care customers: Historically important for Critical Care, including anesthesiologists, intensivists, perfusion teams, and perioperative staff.
International distributors and government-backed health systems: In some regions, Edwards reaches the market through channel partners or tender-based systems rather than a fully direct model.

Overall, Edwards is not dependent on a single consumer segment. It is concentrated in hospital-based cardiovascular care, but diversified across multiple clinician groups and care settings within that domain.

8. What Is the Sales Model of Edwards Lifesciences?

Edwards primarily uses a direct sales model in major developed markets, supported by highly specialized clinical field teams. These teams do more than sell: they educate clinicians, support initial cases, help hospitals implement workflows, and translate clinical evidence into account plans. In selected international markets, Edwards supplements direct coverage with distributors.

The sales process is long and consultative. A hospital does not simply reorder a commodity product; it often builds or expands a structural-heart program, secures reimbursement, trains physicians, and standardizes around preferred devices. That makes sales-force quality and account management unusually important. In Critical Care, the historical model included installed-capital platforms that drove recurring consumable sales. For consultants, this channel structure creates clear opportunities in sales-force effectiveness, account segmentation, international distributor strategy, and launch planning for new therapies.

9. In What Geographies Does Edwards Lifesciences Operate?

Edwards operates globally. The United States is its largest market, but Europe and Japan are also important for structural-heart adoption, and Asia-Pacific and other international markets offer longer-term growth potential. The company sells through a mix of direct commercial organizations and distributors, depending on the country and therapy area.

Operationally, Edwards has a footprint that includes headquarters in Irvine, California, along with manufacturing and operations in the United States and internationally, including sites in places such as Utah, Puerto Rico, the Dominican Republic, and Singapore. Its commercial and clinical-support footprint extends across North America, Europe, Japan, Asia-Pacific, Latin America, and other regions. Edwards is therefore geographically diversified, but still economically concentrated in markets with established reimbursement and trained structural-heart centers.

10. Who Are the Owners of Edwards Lifesciences?

Edwards is a publicly traded company and does not have a controlling shareholder. As disclosed in early 2024 SEC filings, its ownership base was led by large institutional investors, with The Vanguard Group and BlackRock among the most significant holders. Like many large-cap U.S. medtech companies, Edwards is effectively controlled by a broad public shareholder base rather than a founder, family, or government owner.

11. How Is Edwards Lifesciences Organized?

As of FY2023, Edwards reported one reportable segment, even though the business is managed and discussed through distinct product groups. In practical terms, the company has been organized around TAVR, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care, supported by global functions such as R&D, manufacturing, regulatory, quality, clinical affairs, and commercial operations.

This distinction matters. The official financial reporting structure is simpler than the real operating structure. Day to day, Edwards behaves like a portfolio of related cardiovascular franchises that share technology, clinical, and regulatory capabilities. If the announced Critical Care divestiture is completed, the company’s practical organization should become even more centered on structural-heart therapies.

12. How Does Edwards Lifesciences Operate?

Develop therapies: Edwards designs implantable devices, delivery systems, and related technologies, often over long development cycles.
Run clinical studies and secure approvals: New products in structural heart require rigorous trials, regulatory submissions, and post-approval evidence generation.
Manufacture and sterilize products: Implantable valves and catheter systems must be produced under strict quality and traceability requirements.
Train physicians and support cases: Adoption depends heavily on proctoring, training, and field clinical support, especially for early-stage therapies.
Serve hospitals and manage accounts: Edwards works with hospitals on product access, inventory, economics, and program development.
Monitor outcomes and improve platforms: Post-market surveillance, physician feedback, and iterative product development are ongoing parts of the operating model.

The operational complexity is high. Edwards must manage regulated manufacturing, limited procedural capacity at hospitals, physician learning curves, reimbursement variation by country, and the need to keep evidence generation moving while commercializing existing products. In structural heart, execution is as important as invention.

13. What Are the Growth Opportunities for Edwards Lifesciences?

Further TAVR penetration: Many patients with severe valve disease remain untreated or are treated later than ideal. Continued penetration in diagnosed populations, plus geographic expansion, remains a major growth lever.
Longer-run TMTT expansion: Mitral and tricuspid disease represent large markets. If Edwards can translate early approvals and launches into routine adoption, this could become the company’s next major growth engine.
RESILIA-led surgical growth: Edwards can continue to gain traction in surgery through durability messaging and broader use of RESILIA-enabled valves and conduits.
International expansion: Structural-heart therapies still have room to grow outside the United States, especially where heart-center infrastructure and reimbursement are improving.
Portfolio focus after the announced Critical Care sale: A more focused Edwards could allocate management time and capital more aggressively to structural-heart innovation and commercialization.
Selective M&A and pipeline building: Edwards has historically used tuck-in acquisitions to add technologies in mitral and tricuspid disease. That remains a plausible growth path.

The main constraints are equally important: clinical-trial risk, regulatory timing, physician training needs, procedure-capacity limits at hospitals, competition from Abbott and Medtronic, and reimbursement pressure in some geographies.

14. What Is the History of Edwards Lifesciences?

1958: The company’s roots trace to engineer Miles “Lowell” Edwards and surgeon Albert Starr, whose work helped launch modern artificial heart valves.
1960: The first successful Starr-Edwards artificial heart valve was implanted, establishing the company’s historical place in cardiac-device innovation.
1960s-1980s: Edwards Laboratories became part of larger healthcare groups, first American Hospital Supply and later Baxter after Baxter acquired American Hospital Supply in 1985.
2000: Edwards Lifesciences was spun out of Baxter as an independent public company focused on heart valves and hemodynamic monitoring.
2010s: Edwards became one of the defining companies in TAVR as the SAPIEN platform expanded through new approvals and broader patient indications.
Mid-2010s onward: The company broadened its structural-heart pipeline through acquisitions and internal development in mitral and tricuspid therapies, while also strengthening the RESILIA surgical franchise.
2024: Edwards received U.S. approval for EVOQUE in tricuspid regurgitation and announced an agreement to sell its Critical Care product group to BD, marking an important portfolio turning point.

15. What Are the Key Brands Owned by Edwards Lifesciences?

SAPIEN: Edwards’ flagship TAVR franchise and its most strategically important brand. The SAPIEN name carries strong physician recognition and is central to the company’s identity.
PASCAL: A transcatheter mitral and tricuspid repair platform that supports Edwards’ expansion beyond aortic disease.
EVOQUE: A transcatheter tricuspid replacement platform and one of Edwards’ most important newer brands as TMTT scales.
RESILIA: A proprietary tissue-technology brand used across several surgical products. It is important because it helps Edwards frame durability and innovation in surgical valves.
INSPIRIS RESILIA, MITRIS RESILIA, and KONECT RESILIA: Surgical structural-heart brands that matter commercially and strategically, especially for surgeon relationships.
Carpentier-Edwards and PERIMOUNT: Legacy surgical brands that remain relevant because they carry a long clinical history.
HemoSphere, FloTrac, Acumen, and Swan-Ganz: Historically important Critical Care brands with strong clinician recognition in monitoring and hemodynamics.

Branding is important at Edwards, but in a clinical rather than consumer sense. Product-brand trust, evidence, and familiarity can materially influence physician adoption and hospital standardization.

16. How Does the Supply Chain of Edwards Lifesciences Function?

Supply chain is strategically important for Edwards because it sells regulated implantable devices used in life-critical procedures. The company must source specialized biological materials, metals, polymers, catheter components, sensors, packaging, and sterilization services under strict quality and traceability controls. In structural heart, supplier changes can be difficult because they may require validation, regulatory review, or both.

The supply chain includes procurement of highly specified inputs, precision manufacturing and assembly, sterilization, inventory positioning near key markets, and dependable delivery to hospitals performing scheduled and urgent procedures. For a company like Edwards, reliability matters almost as much as cost. Hospitals and physicians need confidence that the right product sizes and accessories will be available for complex cases. That makes supply-chain resilience, supplier qualification, and inventory planning meaningful strategic capabilities rather than back-office tasks.

17. What Is the Technology Strategy of Edwards Lifesciences?

Edwards’ technology strategy is centered on clinically differentiated device platforms. In structural heart, that means better valve durability, smaller and easier delivery systems, improved steerability and placement, and therapy designs that address anatomically challenging mitral and tricuspid disease. Proprietary tissue science, catheter engineering, and implantation workflow design are all part of the technology moat.

Technology also matters as an internal enabler. Edwards needs advanced design controls, manufacturing automation, quality systems, and data from post-market use to improve next-generation platforms. In its historical Critical Care business, technology included predictive hemodynamic algorithms and monitoring software layered onto sensors and catheters. Overall, technology is central to competitiveness because Edwards sells outcomes and procedural confidence, not commodity hardware.

18. What Is the R&D Strategy of Edwards Lifesciences?

R&D is one of Edwards’ defining strategic priorities. The company has consistently invested heavily in research and development, spending more than $1 billion in FY2023. That is a high level for a medtech company and reflects how much of Edwards’ future depends on maintaining a clinically differentiated pipeline.

The R&D agenda spans incremental improvements and new platforms. On one end, Edwards continues to refine leading franchises such as SAPIEN and RESILIA-enabled surgical products. On the other, it funds longer-cycle programs in mitral and tricuspid disease that require new device architectures, extensive clinical trials, and careful physician training. Edwards also complements internal R&D with selective acquisitions of earlier-stage technologies. In effect, R&D at Edwards is not a support function; it is the main engine of long-term growth.

19. What Is the Finance Strategy of Edwards Lifesciences?

Edwards’ finance strategy has historically balanced three priorities: reinvest heavily in innovation, preserve balance-sheet flexibility, and return excess cash through share repurchases rather than through a regular dividend. The company’s high-margin device mix and solid cash generation support this approach.

Capital allocation has tended to favor R&D, manufacturing and supply-chain capability, selective tuck-in M&A, and buybacks. Edwards has generally not relied on high leverage as a core element of strategy. The announced June 2024 sale of Critical Care to BD, if completed, would add substantial cash and could further increase flexibility for portfolio investment, repurchases, or additional structural-heart deals. Finance is therefore tightly linked to strategy: the company uses its balance sheet to preserve optionality while funding innovation at scale.

20. What Major Acquisitions Has Edwards Lifesciences Made?

Edwards has generally used acquisitions to add specific technologies rather than to pursue large-scale roll-up consolidation. Its M&A pattern is targeted and capability-driven.

CardiAQ Valve Technologies (2015): Brought Edwards earlier-stage transcatheter mitral replacement technology and expanded its structural-heart pipeline beyond aortic disease.
Valtech Cardio (2017): Added the Cardioband system and strengthened Edwards’ position in mitral and tricuspid repair technologies.
Harpoon Medical (2017): Added beating-heart mitral repair technology and broadened the company’s mitral innovation portfolio.
CAS Medical Systems (2017): Expanded Edwards’ Critical Care capabilities through monitoring technologies including cerebral oximetry.

These deals show the logic of Edwards’ acquisition strategy: buy technologies that can extend the structural-heart platform or add clinically adjacent capabilities. On the portfolio-reshaping side, the June 2024 announced sale of Critical Care to BD was not an acquisition, but it may prove just as strategically important because it redefines what Edwards wants to be.

21. How Companies Like Edwards Lifesciences Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Edwards Lifesciences use Umbrex when they want that level of problem-solving skill and functional depth, but do not need a full traditional consulting team with all the overhead. For a company with Edwards’ mix of innovation, regulated operations, global commercialization, and portfolio reshaping, independent consultants can be especially useful on targeted, high-value initiatives.

Build a market-entry and launch playbook for newer transcatheter mitral and tricuspid therapies, including account prioritization, physician-segmentation logic, and launch metrics.
Support post-announcement separation planning and operating-model redesign related to the Critical Care divestiture, including transition-service planning and stand-up of a more focused structural-heart organization.
Redesign global commercial coverage for structural-heart accounts, including sales-force sizing, role clarity between reps and clinical specialists, and productivity dashboards.
Develop reimbursement and health-economics strategies for new valve platforms in the United States, Europe, Japan, and selected growth markets.
Run a supply-chain resilience program for tissue valves and catheter systems, including supplier-risk mapping, inventory strategy, and manufacturing-network scenario planning.
Create an R&D portfolio-prioritization model that helps leadership allocate capital across TAVR extensions, TMTT platforms, surgical innovations, and tuck-in technology bets.
Assess and improve launch readiness for EVOQUE, PASCAL, or other newer structural-heart products, including field training, center onboarding, and procedural support workflows.
Evaluate M&A targets or partnership candidates in structural heart, including technology screening, commercial diligence, and post-merger integration planning.
Design analytics and AI-enabled tools for demand forecasting, field inventory optimization, procedure-capacity planning, and commercial performance tracking.
Support international go-to-market strategy in distributor-led markets, including channel design, pricing architecture, and governance for emerging-market expansion.